Prospective Study of TW in the Treatment of LN Type V With Gross Proteinuria
Not Applicable
Completed
- Conditions
- Lupus NephritisProteinuriaCTX
- Interventions
- Registration Number
- NCT00935389
- Lead Sponsor
- Nanjing University School of Medicine
- Brief Summary
The purpose of this study is to analyze the clinical effects and adverse reactions of tripterygium glycosides (TW) and CTX in LN-V patients with gross proteinuria.
- Detailed Description
Compared with cyclophosphamide(CTX), to analyze the clinical effects and adverse reactions of tripterygium glycosides (TW) in LN-V patients with gross proteinuria.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
- SLE patients aging 18-60 years, all of whom comply to the ISN/RPS classification.
- Urine protein≥3.0g/24h, Alb<30g/L and Scr<1.5mg/dL.
- All cases are type IV, confirmed by renal biopsy.
- All patients sign the informed consent and be willing to follow-up on time
Exclusion Criteria
- Accepted drug therapy, such as CTX MMF CsA FK506 or TW more than 2 weeks in the latest 3 months.
- Scr level above 1.5mg/dL, lasts more than 3 months.
- Heart, lung or central nervous systems involved or combined with severe infection.
- With liver function abnormal, ALT or AST being two times above the normal.
- Pregnant women or patients still in lactation.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description immunosuppressor tripterygium glycosides TW 30mg,q.d.\*3 months and reduced into 20mg b.i.d
- Primary Outcome Measures
Name Time Method To analyze the clinical effects of tripterygium glycosides (TW) in LN-V patients with gross proteinuria. 48 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Research Institute of Nephrology, Jinling Hospital
🇨🇳Nanjing, Jiangsu, China
Research Institute of Nephrology,Jinling Hospital
🇨🇳Nanjing, Jiangsu, China